Environment & Lung Cancer

Status Recruiting

Clinical Trial Summary

Cannabis is the most consumed drug in the world and the French are the main consumers in Europe. The most recognized effects of cannabis on human health are of a neuro-psychic nature. The medical literature on the effects of cannabis on the lung in general, and on lung carcinogenesis in particular, is most often reassuring (Tashkin, Chest 2018; Zhang, Int J Cancer 2015; Ghasemiesfe JAMA Netw. Open. 2019), despite the fact that the concentration of carcinogens in cannabis smoke is higher than that contained in tobacco smoke (Moir, Chem. Res. Toxicol. 2008), and that cannabis smoking has been implicated in the occurrence of ENT cancers. Rather, research focuses on the therapeutic effects of cannabis, especially analgesics, and even on its possible anti-tumor virtues (Abrams, Jama Oncol. 2020). These reassuring data should, however, be viewed with a great deal of caution. On the one hand, the illegal nature of cannabis in most countries and its frequent association with tobacco consumption make studies on the subject difficult and often biased. On the other hand, the daily practice of oncologists, who observe numerous cases of advanced and rapidly progressive lung cancer occurring in young patients who are heavy users of cannabis, raises suspicion of an unrecognized role of cannabis in lung carcinogenesis. In a preliminary multicenter study on French patients under 50 years of age operated for primary lung cancer (Betser, ERJ 2021), we demonstrated that cannabis consumption was extremely frequent, concerning 43% of patients, but mentioned in patients' medical records only in 4 out of 10 cases, while the smoking status was always noted. In addition, by comparing people who smoke cannabis (always here associated with tobacco) to patients who only smoke tobacco or to non-smokers, we identified a different profile of lung cancers, with more poorly differentiated tumors, presenting at a more advanced stage (more T3-T4 versus T1-T2) requiring more complex surgery, and mostly located in the upper lobes of the lung. Similar research work is currently underway at Gustave Roussy (Dr Pradere-Dr Planchard, Villejuif, France) on patients with metastatic lung cancer, with a focus on overall survival and molecular profile.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05119244
Study type	Interventional
Source	Centre Chirurgical Marie Lannelongue
Contact	Pauline PRADERE, MD
Phone	01.40.94.22.79
Email	p.pradere@ghpsj.fr
Status	Recruiting
Phase	N/A
Start date	October 1, 2021
Completion date	October 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03253926` - Effect of Lorcaserin on Cannabis Withdrawal and Self-administration	Phase 1/Phase 2
Completed	`NCT04060602` - Personalized Feedback Intervention to Reduce Risky Cannabis Use.	N/A
Completed	`NCT01212081` - Assessment of Cannabis Craving in Schizophrenia Using Virtual Reality
Recruiting	`NCT04988490` - Quantification of Cannabinoids and Comparison to Post-Surgical Pain Medication Requirements and Surgical Outcomes
Recruiting	`NCT05188404` - Aging and Marijuana: Benefits, Effects, and Risks
Completed	`NCT03662737` - VRT as a Biomarker of Cerebellar Dysfunction in Chronic Cannabis Use
Not yet recruiting	`NCT05999383` - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration	Phase 2
Terminated	`NCT04436055` - Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
Active, not recruiting	`NCT04374773` - Effects of Pregnancy-associated Hormones on THC Metabolism in Women	Phase 4
Completed	`NCT04316741` - Brief Intervention Combined With Health Coaching Via Social Media for Cannabis Use	N/A
Recruiting	`NCT05396638` - Characterization of Endocannabinoid and Endogenous Opioid Levels in Adolescents With Cannabis Use Disorder	N/A
Recruiting	`NCT05309226` - Cannabis Use in Pregnancy and Downstream Effects on Maternal and Infant Health
Recruiting	`NCT03859089` - Cannabis for Opioid Substitution Trial
Recruiting	`NCT05849636` - Alerta Cannabis: Evaluation of Web-based Tailored Intervention	N/A
Enrolling by invitation	`NCT05521321` - Feasibility and Acceptability of the Cannabis Awareness and Prevention Toolkit	N/A
Recruiting	`NCT04841655` - Tobacco Cessation Among Smokers Under Alcohol and/or Cannabis Treatment
Terminated	`NCT04100590` - Eye Tracking as a Biomarker of Cannabis Effects	Phase 2
Completed	`NCT05167097` - Mindsets and the Effectiveness of a Brief Intervention - Replication	N/A
Recruiting	`NCT04114903` - Exploring the Anti-inflammatory Properties of Cannabis and Their Relevance to Insulin Sensitivity
Completed	`NCT05170217` - Reducing the Harmful Effects of Cannabis Use: Finding the Optimal CBD:THC Ratio	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Environment and Lung Cancer — PPE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms